SCHEMBL4814554

SCHEMBL4814554

CC(C)CNC(=O)C(NCCOC(N)=O)C(O)[CH]Cc1ccccc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.38
MAPT P10636 2/20 0.38
KMT2A Q03164 2/20 0.38
ALDH1A1 P00352 1/20 0.38
LMNA P02545 1/20 0.37
HPGD P15428 1/20 0.36
CTSD P07339 4/20 0.36
LAP3 P28838 2/20 0.35
ANPEP P15144 1/20 0.35
RNPEP Q9H4A4 1/20 0.35
DNPEP Q9ULA0 1/20 0.35
CTSL P07711 1/20 0.35
CTSS P25774 1/20 0.35
USP2 O75604 2/20 0.35
CYP3A4 P08684 2/20 0.35
NR1I2 O75469 1/20 0.35
ADRB1 P08588 1/20 0.35
HTR1A P08908 1/20 0.35
ADRA2A P08913 1/20 0.35
ADORA3 P0DMS8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4817379 0.82 LMNA (0.40) MEN1MAPTKMT2AALDH1A1LMNA
SCHEMBL4818602 0.81 MAPT (0.38) MEN1MAPTKMT2AALDH1A1LMNA
SCHEMBL4814562 0.70 LAP3 (0.49) MEN1MAPTKMT2AALDH1A1CTSD
SCHEMBL7491376 0.67 LMNA (0.41) MAPTLMNACTSLCTSSCYP1A2
SCHEMBL9209745 0.66 CYP1A2 (0.51) MEN1KMT2AALDH1A1LMNAANPEP
SCHEMBL28969891 0.63 CA2 (0.55) LMNALAP3ANPEPRNPEPDNPEP
SCHEMBL27593026 0.63 KMT2A (0.57) MEN1MAPTKMT2AALDH1A1LMNA
SCHEMBL4253384 0.63 BCHE (0.49) MEN1MAPTKMT2AALDH1A1LMNA
SCHEMBL19975169 0.63 KMT2A (0.60) MEN1MAPTKMT2AALDH1A1LMNA
SCHEMBL13765364 0.63 NAAA (0.58) MEN1MAPTKMT2AALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7354943-B2 Statine derivatives for the treatment of Alzheimer's disease PHARMACIA & UPJOHN (US) 2008-04-08 US claimed
US-20050165069-A1 Statine derivatives for the treatment of Alzheimer's disease ALZHEIMER'S COLLABORATION 2005-07-28 US claimed
US-20050159459-A1 Statine derivatives for the treatment of Alzheimer's disease ALZHEIMER'S COLLABORATION 2005-07-21 US claimed
EP-1404328-A1 ALPHA-HYDROXYAMIDE STATINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE Elan Pharmaceuticals, Inc. (US) 2004-04-07 EP claimed
US-20030083356-A1 Statine derivatives for the treatment of Alzheimer's disease PHARMACIA & UPJOHN 2003-05-01 US claimed
WO-2003006021-A1 ALPHA-HYDROXYAMIDE STATINE DERIVATIVES FOR THE TREATMENT OF ALZH EIMER'S DISEASE ELAN PHARMACEUTICALS, INC. (US) 2003-01-23 WO claimed
US-7358264-B2 Statine derivatives for the treatment of Alzheimer's disease PHARMACIA & UPJOHN COMPANY (US) 2008-04-15 US disclosed
US-7354943-B2 Statine derivatives for the treatment of Alzheimer's disease PHARMACIA & UPJOHN (US) 2008-04-08 US disclosed
US-20050165069-A1 Statine derivatives for the treatment of Alzheimer's disease ALZHEIMER'S COLLABORATION 2005-07-28 US disclosed
US-20050159459-A1 Statine derivatives for the treatment of Alzheimer's disease ALZHEIMER'S COLLABORATION 2005-07-21 US disclosed
US-6864290-B2 Statine derivatives for the treatment of Alzheimer's disease PHARMACIA & UPJOHN, LLP (US) 2005-03-08 US disclosed
EP-1404328-A1 ALPHA-HYDROXYAMIDE STATINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE Elan Pharmaceuticals, Inc. (US) 2004-04-07 EP disclosed
US-20030083356-A1 Statine derivatives for the treatment of Alzheimer's disease PHARMACIA & UPJOHN 2003-05-01 US disclosed
WO-2003006021-A1 ALPHA-HYDROXYAMIDE STATINE DERIVATIVES FOR THE TREATMENT OF ALZH EIMER'S DISEASE ELAN PHARMACEUTICALS, INC. (US) 2003-01-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050165069-A1 Statine derivatives for the treatment of Alzheimer's disease BACE1, APP, BACE2 MEN1 1804/4885MAPT 29/4885KMT2A 3384/4885
US-20050159459-A1 Statine derivatives for the treatment of Alzheimer's disease BACE1, APP, BACE2 MEN1 1804/4885MAPT 29/4885KMT2A 3384/4885
US-20030083356-A1 Statine derivatives for the treatment of Alzheimer's disease BACE1, APP, BACE2 MEN1 1550/4885MAPT 51/4885KMT2A 3578/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.